BCL2 and non-Hodgkin lymphoma: Zn-d5: Zn-d5 is a selective BCL2 inhibitor developed by Zentalis Pharmaceuticals (https://www.zentalis.com) which reportedly demonstrates significant single-agent and combination anti-tumor activity in xenograft models of NHL, AML, and other hematological and solid tumor types.344 It has been under clinical assessment for R/R NHL, AML and light chain amyloidosis.